title: Pharmacological considerations for the proper clinical use of aminoglycosides.
abstract: Aminoglycosides constitute one of the oldest classes of antimicrobials. Despite their toxicity, mainly nephrotoxicity and ototoxicity, aminoglycosides are valuable in current clinical practice, since they retain good activity against multidrug-resistant Gram-negative pathogens, such as Pseudomonas aeruginosa and Acinetobacter spp. Time-kill studies have shown a concentration-dependent and partially concentration-dependent bacterial killing against Gram-negative and Gram-positive bacteria, respectively. Pharmacodynamic data gathered over recent decades show that the administration of aminoglycosides by an extended-interval dosing scheme takes advantage of the maximum potential of these agents, with the goal of achieving an area under the concentration-time curve (AUC) of 100 mg · h/L over 24 hours and a peak plasma drug concentration (C(max)) to minimum inhibitory concentration (MIC) ratio of 8-10. Several clinical conditions that are common in seriously ill patients result in expansion of the extracellular space and can lead to a lower than desirable C(max) with the usual loading dose. Extended-interval dosing schemes allow adequate time to decrease bacterial adaptive resistance, a phenomenon characterized by slow concentration-independent killing. Adaptive resistance is minimized by the complete clearance of the drug before the subsequent dose, thus favouring the extended-interval dosing schemes. The efficacy of these schemes is also safeguarded by the observed post-antibiotic sub-MIC effect and post-antibiotic leukocyte enhancement, which inhibit bacterial regrowth when the serum aminoglycoside levels fall below the MIC of the pathogen. In everyday clinical practice, aminoglycosides are usually used empirically to treat severe sepsis and septic shock while awaiting the results of antimicrobial susceptibility testing. The European Committee on Antimicrobial Susceptibility Testing acknowledges the regimen-dependent nature of clinical breakpoints for aminoglycosides, i.e. of MIC values that classify bacterial isolates into sensitive or resistant, and bases its recommendations on extended-interval dosing. To a large extent, the lack of correlation between in vitro antimicrobial susceptibility testing and clinical outcome is derived from the fact that the available clinical breakpoints for aminoglycosides are set based on mean pharmacokinetic parameters obtained in healthy volunteers and not sick patients. The nephrotoxicity associated with once- versus multiple-daily administration of aminoglycosides has been assessed in numerous prospective randomized trials and by several meta-analyses. The once-daily dosing schedule provides a longer time of administration until the threshold for nephrotoxicity is met. Regarding ototoxicity, no dosing regimen appears to be less ototoxic than another. Inactivation of aminoglycosides inside the bacterial pathogens occurs by diverse modifying enzymes and by operation of multidrug efflux systems, making both of these potential targets for inhibition. In summary, despite their use for several decades, the ideal method of administration and the preferred dosing schemes of aminoglycosides for most of their therapeutic indications need further refinement. Individualized pharmacodynamic monitoring has the potential of minimizing the toxicity and the clinical failures of these agents in critically ill patients.
authors.affiliation: Department of Pediatrics, Democritus University of Thrace Medical School, Alexandroupolis, Thrace, Greece.
authors.forename: Spyridon
authors.initials: S
authors.lastname: Pagkalis
authors.forename: Elpis
authors.initials: E
authors.lastname: Mantadakis
authors.forename: Michael N
authors.initials: MN
authors.lastname: Mavros
authors.forename: Christina
authors.initials: C
authors.lastname: Ammari
authors.forename: Matthew E
authors.initials: ME
authors.lastname: Falagas
mesh_terms: D000617:Aminoglycosides / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D001424:Bacterial Infections / Q000188:drug therapy*; D006801:Humans
chemical_list: D000617:Aminoglycosides
references.citation: Br J Clin Pharmacol. 2011 Jan;71(1):61-71
references.pmid: 21143502
references.citation: Antimicrob Agents Chemother. 1995 Mar;39(3):650-5
references.pmid: 7793867
references.citation: J Clin Microbiol. 2008 Aug;46(8):2717-22
references.pmid: 18508940
references.citation: Antimicrob Agents Chemother. 1996 Mar;40(3):784-6
references.pmid: 8851612
references.citation: Antimicrob Agents Chemother. 2004 Dec;48(12):4606-10
references.pmid: 15561832
references.citation: Clin Infect Dis. 2000 Mar;30(3):454-60
references.pmid: 10722427
references.citation: Int J Antimicrob Agents. 2003 Dec;22(6):551-6
references.pmid: 14659650
references.citation: J Clin Pharmacol. 2006 Nov;46(11):1259-67
references.pmid: 17050791
references.citation: N Engl J Med. 1982 Sep 9;307(11):652-9
references.pmid: 7050706
references.citation: J Infect Dis. 1993 Jan;167(1):173-9
references.pmid: 8418164
references.citation: J Infect Dis. 1988 Jul;158(1):7-12
references.pmid: 3392422
references.citation: Antimicrob Agents Chemother. 2008 Nov;52(11):3987-93
references.pmid: 18725438
references.citation: Clin Pharmacokinet. 2005;44(2):201-10
references.pmid: 15656698
references.citation: Antimicrob Agents Chemother. 2003 Apr;47(4):1371-5
references.pmid: 12654672
references.citation: J Clin Pharmacol. 2004 Jul;44(7):696-707
references.pmid: 15199074
references.citation: Rev Infect Dis. 1981 Jan-Feb;3(1):38-44
references.pmid: 7012999
references.citation: Int J Antimicrob Agents. 2009 Mar;33(3):201-5
references.pmid: 18976888
references.citation: Surgery. 1998 Jul;124(1):73-8
references.pmid: 9663254
references.citation: J Physiol. 2005 Sep 1;567(Pt 2):505-21
references.pmid: 15994187
references.citation: J Chemother. 1995 Aug;7(4):355-62
references.pmid: 8568546
references.citation: Anaesth Intensive Care. 2008 Sep;36(5):674-80
references.pmid: 18853585
references.citation: Acta Anaesthesiol Scand. 1999 Aug;43(7):726-30
references.pmid: 10456812
references.citation: Rev Laryngol Otol Rhinol (Bord). 1993;114(2):125-8
references.pmid: 8284554
references.citation: Chemotherapy. 1991;37(2):114-21
references.pmid: 1903340
references.citation: Jpn J Antibiot. 1988 May;41(5):523-9
references.pmid: 3216474
references.citation: Antimicrob Agents Chemother. 1991 Sep;35(9):1834-9
references.pmid: 1952854
references.citation: J Antimicrob Chemother. 2003 Oct;52(4):668-74
references.pmid: 12951354
references.citation: Ann Intern Med. 1996 Apr 15;124(8):717-25
references.pmid: 8633831
references.citation: J Antimicrob Chemother. 1996 Jun;37(6):1155-64
references.pmid: 8836818
references.citation: J Clin Pharmacol. 1977 Feb-Mar;17(2-3):108-19
references.pmid: 833341
references.citation: Antimicrob Agents Chemother. 1999 Dec;43(12):2975-83
references.pmid: 10582892
references.citation: Cochrane Database Syst Rev. 2009 Oct 07;(4):CD004197
references.pmid: 19821321
references.citation: J Antimicrob Chemother. 2008 Mar;61(3):621-8
references.pmid: 18252694
references.citation: J Antimicrob Chemother. 1994 May;33(5):937-47
references.pmid: 8089067
references.citation: J Infect Dis. 1982 Nov;146(5):691-7
references.pmid: 6813385
references.citation: Clin Infect Dis. 2007 Sep 15;45(6):753-60
references.pmid: 17712761
references.citation: Antimicrob Agents Chemother. 2010 Jan;54(1):312-9
references.pmid: 19822705
references.citation: J Antimicrob Chemother. 1988 Jul;22(1):23-33
references.pmid: 3139614
references.citation: J Antimicrob Chemother. 2005 May;55(5):699-706
references.pmid: 15772138
references.citation: Annu Rev Microbiol. 2010;64:357-72
references.pmid: 20528688
references.citation: Clin Infect Dis. 2001 May 15;32 Suppl 2:S146-55
references.pmid: 11320454
references.citation: J Antimicrob Chemother. 2011 Feb;66(2):251-9
references.pmid: 21131321
references.citation: PLoS Comput Biol. 2011 Jan 06;7(1):e1001043
references.pmid: 21253559
references.citation: Clin Pharmacokinet. 1987 Oct;13(4):228-53
references.pmid: 3311531
references.citation: PLoS One. 2008 Feb 20;3(2):e1619
references.pmid: 18286176
references.citation: Br J Clin Pharmacol. 1995 Jun;39(6):605-9
references.pmid: 7654477
references.citation: Anaesth Intensive Care. 1993 Apr;21(2):172-3
references.pmid: 8517507
references.citation: Am J Surg. 1966 Jun;111(6):813-8
references.pmid: 5931526
references.citation: Int J Antimicrob Agents. 2006 Mar;27(3):247-52
references.pmid: 16472992
references.citation: Antimicrob Agents Chemother. 1990 Feb;34(2):332-6
references.pmid: 2109580
references.citation: Clin Ther. 2001 Aug;23(8):1231-44
references.pmid: 11558860
references.citation: J Clin Pharm Ther. 1995 Oct;20(5):253-8
references.pmid: 8576291
references.citation: J Antimicrob Chemother. 2009 May;63(5):1043-9
references.pmid: 19299469
references.citation: J Infect Dis. 1984 Nov;150(5):778-9
references.pmid: 6436396
references.citation: Pharmacotherapy. 1999 Nov;19(11):1252-60
references.pmid: 10555931
references.citation: Antimicrob Agents Chemother. 1999 Jul;43(7):1549-55
references.pmid: 10390201
references.citation: Antimicrob Agents Chemother. 2010 Nov;54(11):4636-42
references.pmid: 20805391
references.citation: Hear Res. 2010 Sep 1;268(1-2):250-9
references.pmid: 20561573
references.citation: Antimicrob Agents Chemother. 2006 Nov;50(11):3763-9
references.pmid: 17065622
references.citation: J Clin Pharmacol. 2001 Apr;41(4):374-7
references.pmid: 11304893
references.citation: J Antimicrob Chemother. 1989 Apr;23(4):565-76
references.pmid: 2663813
references.citation: Antimicrob Agents Chemother. 1987 Jul;31(7):1054-60
references.pmid: 3116917
references.citation: Int J Antimicrob Agents. 2001 Jan;17(1):1-8
references.pmid: 11137642
references.citation: Antimicrob Agents Chemother. 1992 Mar;36(3):679-81
references.pmid: 1622185
references.citation: J Infect Dis. 1992 Oct;166(4):923-6
references.pmid: 1445599
references.citation: Clin Infect Dis. 2007 Jan 1;44(1):79-86
references.pmid: 17143821
references.citation: Ren Fail. 1992;14(3):351-7
references.pmid: 1509168
references.citation: Ther Drug Monit. 2008 Dec;30(6):674-81
references.pmid: 19057371
references.citation: J Med Microbiol. 2009 Aug;58(Pt 8):1067-1073
references.pmid: 19528167
references.citation: Biochem Pharmacol. 1986 Mar 15;35(6):979-84
references.pmid: 3006697
references.citation: Anesthesiology. 1993 Oct;79(4):685-94
references.pmid: 8105728
references.citation: Clin Pharmacol Ther. 1997 Jul;62(1):106-11
references.pmid: 9246024
references.citation: Microb Pathog. 2010 Jan;48(1):18-27
references.pmid: 19825410
references.citation: Nature. 2005 Aug 25;436(7054):1171-5
references.pmid: 16121184
references.citation: Thorax. 2010 Apr;65(4):286-91
references.pmid: 19996339
references.citation: J Infect Dis. 1977 Feb;135(2):217-23
references.pmid: 839090
references.citation: Antimicrob Agents Chemother. 1992 Sep;36(9):1852-8
references.pmid: 1329631
references.citation: Int J Pharm. 2009 May 21;373(1-2):141-6
references.pmid: 19429299
references.citation: J Antimicrob Chemother. 1999 Aug;44(2):235-42
references.pmid: 10473231
references.citation: Am J Med. 1990 Jul;89(1):58-66
references.pmid: 2195890
references.citation: Pharmacotherapy. 2010 Jan;30(1):43-51
references.pmid: 20030472
references.citation: Eur J Clin Pharmacol. 1990;39(2):199-201
references.pmid: 2253677
references.citation: Clin Pharmacol Ther. 1986 Mar;39(3):325-8
references.pmid: 3948471
references.citation: Antimicrob Agents Chemother. 2010 Nov;54(11):4939-41
references.pmid: 20823287
references.citation: Cochrane Database Syst Rev. 2010 Jan 20;(1):CD002009
references.pmid: 20091528
references.citation: Appl Environ Microbiol. 2006 Mar;72(3):2005-13
references.pmid: 16517649
references.citation: Hear Res. 2009 Jul;253(1-2):32-41
references.pmid: 19285126
references.citation: J Antimicrob Chemother. 2003 Feb;51(2):347-52
references.pmid: 12562701
references.citation: Am J Physiol. 1988 Aug;255(2 Pt 2):F265-9
references.pmid: 2457327
references.citation: Diagn Microbiol Infect Dis. 2005 Jun;52(2):123-7
references.pmid: 15964500
references.citation: Antimicrob Agents Chemother. 1996 Jun;40(6):1387-93
references.pmid: 8726006
references.citation: Rev Infect Dis. 1981 Jan-Feb;3(1):28-37
references.pmid: 6784225
references.citation: Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14570-5
references.pmid: 19706543
references.citation: J Clin Pharmacol. 1984 Jan;24(1):43-6
references.pmid: 6707233
references.citation: Scand J Infect Dis Suppl. 1990;74:63-70
references.pmid: 2097720
references.citation: Antimicrob Agents Chemother. 2006 Aug;50(8):2626-31
references.pmid: 16870751
references.citation: Clin Pharmacokinet. 2003;42(5):493-500
references.pmid: 12739987
references.citation: Crit Care. 2010;14(2):R53
references.pmid: 20370907
references.citation: Antimicrob Agents Chemother. 1998 Apr;42(4):749-54
references.pmid: 9559777
references.citation: Diagn Microbiol Infect Dis. 2003 Sep;47(1):361-4
references.pmid: 12967751
references.citation: Antimicrob Agents Chemother. 1992 Sep;36(9):1951-7
references.pmid: 1416886
references.citation: Antimicrob Agents Chemother. 1999 Mar;43(3):623-9
references.pmid: 10049277
references.citation: Kidney Int. 1979 Apr;15(4):335-45
references.pmid: 513493
references.citation: J Biol Chem. 2002 Jan 4;277(1):618-22
references.pmid: 11700326
references.citation: Pediatrics. 2004 Jul;114(1):e111-8
references.pmid: 15231982
references.citation: J Biol Chem. 1997 Oct 3;272(40):24755-8
references.pmid: 9312069
references.citation: Brain Res. 1995 Dec 15;704(1):135-40
references.pmid: 8750975
references.citation: J Antimicrob Chemother. 1993 May;31 Suppl D:149-58
references.pmid: 8335516
references.citation: Intensive Care Med. 1996 May;22(5):443-6
references.pmid: 8796397
references.citation: Toxicology. 2008 Jul 30;249(2-3):91-6
references.pmid: 18514377
references.citation: J Antimicrob Chemother. 1990 Jun;25(6):941-8
references.pmid: 2115038
references.citation: J Infect Dis. 1987 Jan;155(1):93-9
references.pmid: 3540140
references.citation: Biochem Pharmacol. 2006 Mar 30;71(7):910-8
references.pmid: 16427026
references.citation: J Clin Pharmacol. 1990 Sep;30(9):798-801
references.pmid: 2277126
references.citation: Clin Pharmacol Ther. 1997 Oct;62(4):392-9
references.pmid: 9357390
references.citation: J Antimicrob Chemother. 1991 Jun;27(6):829-36
references.pmid: 1938689
references.citation: Clin Pharmacokinet. 2009;48(4):253-63
references.pmid: 19492870
references.citation: J Antimicrob Chemother. 1985 Jan;15 Suppl A:37-46
references.pmid: 3980335
references.citation: Am J Med. 1983 Dec;75(6):943-50
references.pmid: 6650549
references.citation: Arch Orthop Trauma Surg. 2009 Oct;129(10):1301-8
references.pmid: 19034468
references.citation: Noise Health. 2009 Jan-Mar;11(42):26-32
references.pmid: 19265251
references.citation: Glycobiology. 2010 Jul;20(7):895-904
references.pmid: 20348539
references.citation: Br J Clin Pharmacol. 2004 Jul;58(1):8-19
references.pmid: 15206987
references.citation: Curr Opin Microbiol. 2000 Oct;3(5):515-21
references.pmid: 11050452
references.citation: Expert Rev Anti Infect Ther. 2008 Oct;6(5):593-600
references.pmid: 18847400
references.citation: J Antimicrob Chemother. 1991 May;27 Suppl C:29-40
references.pmid: 1830302
references.citation: Antimicrob Agents Chemother. 1974 Jan;5(1):95-7
references.pmid: 4209319
references.citation: Clin Infect Dis. 2000 Mar;30(3):433-9
references.pmid: 10722424
references.citation: Pharmacotherapy. 2001 Apr;21(4):443-51
references.pmid: 11310518
references.citation: Am J Physiol Renal Physiol. 2004 Apr;286(4):F617-24
references.pmid: 14625200
references.citation: Trends Biotechnol. 2007 Dec;25(12):547-55
references.pmid: 17997179
references.citation: Antimicrob Agents Chemother. 1999 May;43(5):1003-12
references.pmid: 10223907
references.citation: Antimicrob Agents Chemother. 1985 Mar;27(3):343-9
references.pmid: 3922294
references.citation: J Infect Dis. 1990 Aug;162(2):414-20
references.pmid: 2115555
references.citation: Antimicrob Agents Chemother. 1991 Jan;35(1):117-23
references.pmid: 2014966
references.citation: Hear Res. 2005 Jun;204(1-2):156-69
references.pmid: 15925201
references.citation: Clin Infect Dis. 2005 Oct 15;41(8):1159-66
references.pmid: 16163635